Biopharmaceutical manufacturing has never been as capable as it is today. Facilities are highly automated, analytical methods are more sensitive than ever, and digital systems now connect operations that once worked in isolation. Organisations have invested heavily in process knowledge, contamination control, data infrastructure and regulatory systems, and on paper their quality systems have never looked stronger.
Despite these investments, many companies still struggle when scrutiny is applied. A regulatory inspection opens, or a product complaint exposes a question the batch record cannot fully answer. A trend that has been visible for months suddenly turns urgent or disruptive. A cross-functional team gathers to respond to the observation or finding, only to find that the facts are scattered, ownership is unclear, and capability is not present. Readiness is absent.
That distinction sits at the heart of this article. Capability is what an organisation can do under planned conditions. Readiness is what it can still do when conditions turn uncertain, compressed, visible and consequential. In manufacturing, that difference often decides whether a company responds with clarity or confusion, whether a regulatory interaction ends in gaining trust or concern, and whether the quality system behaves like a living management system or just a shelf of procedures.
None of this is unfolding in a calm environment. Everything is interconnected, from distributed and interdependent manufacturing networks to volatile supply chains and shifting trade policy that keeps redrawing where and how medicines are made. Geopolitical uncertainty layers on risk that no single site controls, while artificial intelligence moves into manufacturing and quality decisions, offering new insight but raising fresh questions about data, oversight and judgment. Each of these forces adds complexity, and complexity is exactly the condition under which capability and readiness stop being the same thing.
The Capability Trap
Most organisations have product experts and committed employees behind the operation. However, they may still fail under pressure because capability tends to be built in siloed pockets, while scrutiny tests the system as a whole.
In a typical company structure, each function holds part of the picture. Manufacturing knows the process, Quality knows the procedures, Regulatory Affairs knows the commitments, Technical Operations knows the validation history and the laboratory knows the analytical method, while senior leadership carries the business risk. During an inspection, a deviation escalation or a product impact assessment, those separate pieces have to come together quickly into one coherent account: what happened, why it matters, what controls exist, what evidence supports the conclusion and what happens next.
That is where many systems struggle. The gap is seldom a missing procedure. More often it is weak integration: capability without enough shared context, defined roles without clear ownership, or escalation pathways without proven judgment. This is the capability trap, the assumption that technical systems, procedures and qualified people are themselves proof of readiness. Readiness is proven in motion, not on paper.
Scrutiny Has Changed
Scrutiny has become global, transparent and increasingly data informed. Public databases now share manufacturing approvals, certificates and non-compliance findings across jurisdictions, and regulators compare what is written against what is done and what is recorded, often across borders.
The implication for manufacturers is straightforward. Strong technical capability is now assumed, not a differentiator. What regulators, partners and supply-chain stakeholders look for is something harder to fake: evidence that the organisation can detect, explain, govern and correct risk before it creates negative impacts.
The Scrutiny Signal
Recent regulatory data show that quality risk remains active even in a sophisticated industry:
• In FY2024 the U.S. FDA issued 105 quality-related warning letters to human-drug manufacturing sites, the highest figure in five years.
• The same year brought 75 import-alert additions for poor drug-quality reasons and 421 drug recalls.
• An EFPIA survey recorded 82 jurisdictions performing foreign GMP/GDP inspections between 2003 and 2024, and 38 jurisdictions doing so in 2024 alone.
• Public registers such as EudraGMDP in Europe and Health Canada’s inspection tracker now expose authorisations, certificates and non-compliance actions to partners and competitors alike.
The message is consistent: capability is assumed; the differentiator is an organisation’s ability to detect, explain, govern and correct risk before it becomes consequence.
When Pressure Removes the Cushion
Under normal conditions, organisations quietly compensate for weak integration. For example, roles get clarified in the corridor, experienced people remember how similar situations were handled, and an extra meeting usually closes the gap for tense relationships. Given enough time, most issues work themselves out.
Scrutiny removes that slack. An investigator is not only checking whether a procedure exists; they are testing whether the organisation can explain and demonstrate control, and whether what is written, what is done, what is recorded and what people understand actually line up. The same holds during major deviations and high-risk decisions. The technical question may be narrow, but the organisational test is wide: can the team define the issue clearly, separate signal from noise, weigh patient, product, process and compliance risk without distortion, find reliable evidence quickly, and explain its reasoning in a way that is both scientifically sound and credible to a regulator?
When pressure rises, the real operating model shows itself. Ambiguity that was tolerable becomes visible, unclear ownership turns into delay, thin documentation becomes exposure, and cultural habits end up on the record.
This is also why familiar metrics can mislead. A low deviation rate may mean strong control, or it may mean quiet underreporting. Fast CAPA closure may mean discipline, or it may mean shallow remediation. A long run of successful batches may mean genuine robustness, or a growing reliance on a few experts to rescue them. Even a clean inspection may mean real maturity, or simply good preparation for a narrow window of time. Readiness asks leaders to look past the number and ask what the system is actually learning.
Inspections and Deviations Reveal the System
The regulatory inspection is the clearest case. Many organisations prepare hard for one, refreshing training, organising documents, rehearsing experts and testing the logistics. That work matters, but it can leave the impression that inspection readiness is something switched on for the occasion. What an inspection really measures is the readiness an organisation already had before the inspectors arrived.
In a ready organisation, subject-matter experts do more than recite procedures. They understand why a control exists, how their process connects to product quality and patient risk, and how the organisation knows the control is working. In a less ready one, the answers can each be correct yet still fail to add up: one person explains the procedure, another the deviation, a third the CAPA, a fourth the validation history, and no single coherent picture of control emerges. Investigators tend to notice when a story is being assembled for the first time in the room.
Deviation management follows the same logic. Almost everyone has investigation templates, root-cause tools and governance reviews, yet having the process says little about the quality of the thinking inside it. An investigation can be flawless in form and hollow in substance. What matters is whether the organisation reads the event in context. Was human error genuinely the cause, or the last visible link in a chain of design, training, workload, equipment or procedure? Did the response fix the record or strengthen the system? A ready organisation does not mistake speed for haste; it can move fast without abandoning its scientific reasoning.
The stakes climb fastest in advanced therapies. Cell and gene therapy manufacturing brings compressed timelines, patient-specific materials, biological variability and very small batches, and decisions are often made while analytical or process information is still coming in. Capability alone cannot carry that. The organisation needs its decision logic settled before the pressure arrives: predefined escalation criteria, a sound contamination control strategy, disciplined chain of identity and custody, and cross-functional decision-making that already works. The real question is whether the system can perform, explain itself and protect the patient when conditions get difficult.
Leadership as a Control
Leadership is sometimes treated as something separate from the manufacturing and quality systems. That is a mistake, because in a high-pressure environment how leaders behave is itself one of the most important controls. Leaders set the tone for whether issues are escalated early or late, whether teams surface uncertainty or bury it, and whether metrics get used for learning or for reassurance.
The questions a leader asks shape what the organisation lets itself see. Asking only whether work is on track invites comfortable answers. Asking where performance quietly depends on individual heroics exposes the fragile spots, and asking who owns a given risk once the meeting ends is what turns accountability from an idea into a fact. The strongest leaders do not wait for a crisis to learn how their system behaves; they probe it well before the moment of consequence.
Building Readiness
Closing the gap between capability and readiness is not about adding more complexity. Usually it calls for the opposite: a system that is clearer, better connected and readier to decide. A few shifts do most of the work.
Readiness has to be treated as an everyday operating discipline rather than an inspection-prep exercise, woven into daily management, deviation review, risk governance and training. Evidence must be made decision-useful, so the organisation knows which data matter, where they sit and how far they can be trusted. Cross-functional alignment needs to be rehearsed before the pressure arrives, through shared language, clear escalation paths and decisions made in advance rather than improvised around a hard question for the first time. Capability should include judgment, so people can spot a weak signal and explain their reasoning, not merely follow a procedure. Ownership has to outlast the meeting, so risks are tracked and resolved once the discussion breaks up. And the organisation has to get used to working under pressure, because supply constraints, inspection findings, shifting regulations and patient urgency are not the exception; they are the current reality.
The organisations that do this best are the ones that keep their discipline and standards while moving through it.
When the System Speaks
The years ahead will bring more technology advances, more digital systems, and tougher regulatory expectations. All of it will strengthen the industry, and none of it will retire the need for human judgment. If anything, judgment matters more as the systems grow more complex, because complexity still has to be integrated, governed, explained and trusted when someone looks closely.
Capability asks whether an organisation can perform. Readiness asks whether it can perform, understand, explain, adapt and still protect the patient when that is what the moment demands. The decisive moments seldom arrive on a clear calendar with perfect data. They arrive in the middle of inspections, deviations, shortages, technology transfers, accelerated launches and events nobody planned for. In those moments the system speaks for itself, and the only question that matters is whether it speaks with clarity.
Every organisation eventually meets a moment it did not schedule. When it comes, the merely capable begin assembling the story; the ready have already written it into the way they work. That difference rarely shows up on a dashboard, yet it is becoming the truest test of a manufacturing organisation, and the clearest mark of the leaders who build one.
References:
1. U.S. Food and Drug Administration. Report on the State of Pharmaceutical Quality: Fiscal Year 2024. CDER, Office of Pharmaceutical Quality, 2025. (FY2024 quality-related warning letters, import-alert additions and drug recalls.)
2. European Federation of Pharmaceutical Industries and Associations (EFPIA). Annual Regulatory GMP/GDP Inspection Survey — 2024 Data. Published June 2025.
3. Health Canada. Inspection Tracker: Drug Manufacturing Establishments (Government of Canada).
Read the full article — it's free
Register with Pharma Focus America to unlock expert insights, research articles and in-depth industry analysis.
